Related News
Home » Business » Manufacturing
Boehringer Ingelheim to open vaccine R&D center in city
By Ding Yining |
March 12, 2012, Monday
|
Online Edition
Online Edition
GERMAN drug maker Boehringer Ingelheim said today it will invest 12 million euros (US$15.7 million) in an Asian Veterinary Research & Development Center in Shanghai to boost its animal vaccine business.
The research facility will be located in Zhangjiang Hightech Park and focus on developing innovative vaccines targeted at specific diseases among swines and poultry.
This is the first animal health R&D facility set up by a multinational drug maker in China and it's the third one for BI outside Germany and the United States.
"Boehringer Ingelheim is aimed at becoming a top four animal health company within 10 years driven by strong performance in the animal vaccine sector," aid Hubertus von Baumbach, Boehringer Ingelheim board member for finance and animal health.
The German pharmaceutical company is also in the final stage of talks with partners to set up a local manufacturing site for its vaccine products and the announcement will be made in the next few months.
"It's a natural progression for us to move the production site to a local market and in this way we can address local demands more quickly and flexibly," said David Preston, chairman and CEO of Boehringer Ingelheim Shanghai Pharmaceutical Co.
The research facility will be located in Zhangjiang Hightech Park and focus on developing innovative vaccines targeted at specific diseases among swines and poultry.
This is the first animal health R&D facility set up by a multinational drug maker in China and it's the third one for BI outside Germany and the United States.
"Boehringer Ingelheim is aimed at becoming a top four animal health company within 10 years driven by strong performance in the animal vaccine sector," aid Hubertus von Baumbach, Boehringer Ingelheim board member for finance and animal health.
The German pharmaceutical company is also in the final stage of talks with partners to set up a local manufacturing site for its vaccine products and the announcement will be made in the next few months.
"It's a natural progression for us to move the production site to a local market and in this way we can address local demands more quickly and flexibly," said David Preston, chairman and CEO of Boehringer Ingelheim Shanghai Pharmaceutical Co.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
